Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2611 to 2625 of 8910 results

  1. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development Reference number: GID-HTG10170 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  2. Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

    In development Reference number: GID-TA11643 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 6 March 2026.

    Technology appraisal guidance
    In consultation

  4. Selinexor + pomalidomide + dexamethasone for Multiple myeloma [TSID12333]

    Awaiting development Reference number: GID-TA11938 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. SEEG-guided radiofrequency thermocoagulation in refractory epilepsy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  6. Lumella Pre-Eclampsia Test (MT687)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  7. Gemcitabine intravesical delivery system for treating recurrent high-risk papillary non-muscle-invasive bladder after BCG [ID6657]

    Awaiting development Reference number: GID-TA11872 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]

    In development Reference number: GID-TA11424 Expected publication date:  07 May 2026

    Technology appraisal guidance
    In development

  9. Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate [ID6677]

    Awaiting development Reference number: GID-TA11827 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Luspatercept for treating anaemia caused by myelofibrosis [ID6697]

    Awaiting development Reference number: GID-TA11915 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Tozorakimab for treating exacerbations of chronic obstructive pulmonary disease after optimised inhaled dual or triple therapy [ID6711]

    Awaiting development Reference number: GID-TA11944 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Rusfertide for treating polycythaemia vera in people having phlebotomy [ID6709]

    Awaiting development Reference number: GID-TA11937 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]

    In development Reference number: GID-TA11572 Expected publication date:  21 May 2026

    Technology appraisal guidance
    In development

  14. Advanced breast cancer: diagnosis and management (Partial update)

    In development Reference number: GID-NG10430 Expected publication date:  29 May 2026

    NICE guideline
    In development

  15. Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]

    In development Reference number: GID-TA11564 Expected publication date: TBC

    Technology appraisal guidance
    In development